_2020091018165303jzv.jpg "Decoding The World Of ETF")
-
My Account
My Account
BSE Live
Nov 25, 16:00Prev. Close
480.55
Open Price
483.15
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 25, 15:59Prev. Close
480.50
Open Price
484.00
Bid Price (Qty.)
466.30 (620)
Offer Price (Qty.)
0.00 (0)
| Half Yearly Results of Glenmark Pharma (in Rs. Cr.) | Mar '20 | Sep '19 | Mar '19 | Sep '18 | Mar '18 | |
| Net Sales/Income from operations | 3,424.02 | 3,197.86 | 3,130.66 | 3,000.48 | 2,965.57 | |
| Other Operating Income | -- | 90.76 | 88.66 | 85.07 | 258.72 | |
| Total Income From Operations | 3,424.02 | 3,288.61 | 3,219.32 | 3,085.55 | 3,224.29 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 1,165.02 | 1,086.96 | 791.44 | 794.42 | 1,053.72 | |
| Purchase of Traded Goods | 175.76 | 189.49 | 138.51 | 162.79 | 152.46 | |
| Increase/Decrease in Stocks | 38.37 | 10.40 | 314.40 | 157.41 | 4.28 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 506.52 | 565.81 | 456.31 | 513.67 | 487.73 | |
| Depreciation | 73.05 | 65.49 | 52.05 | 54.23 | 59.37 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 923.30 | 746.78 | 900.55 | 747.90 | 928.99 | |
| P/L Before Other | 542.01 | 623.69 | 566.05 | 655.15 | 537.74 | |
| Other Income | 345.78 | 261.01 | 83.75 | 391.87 | 81.53 | |
| P/L Before Int. | 887.79 | 884.69 | 649.80 | 1,047.01 | 619.27 | |
| Interest | 123.15 | 133.24 | 107.79 | 116.02 | 97.72 | |
| P/L Before Exceptional Items & Tax | 764.64 | 751.45 | 542.01 | 930.99 | 521.55 | |
| Exceptional Items | 18.55 | -- | -- | 345.19 | -- | |
| P/L Before Tax | 783.19 | 751.45 | 542.01 | 1,276.17 | 521.55 | |
| Tax | 88.48 | 91.62 | 91.30 | 238.58 | 105.92 | |
| P/L After Tax from Ordinary Activities | 694.71 | 659.84 | 450.71 | 1,037.59 | 415.63 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | 26.45 | 107.36 | -- | |
| Net Profit/(Loss) For the Period | 694.71 | 659.84 | 477.16 | 1,144.95 | 415.63 | |
| Equity Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | |
| Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 24.62 | 23.38 | -- | 40.58 | -- | |
| Diluted EPS | -- | 23.38 | -- | 40.58 | -- | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 24.62 | 23.38 | -- | 40.58 | -- | |
| Diluted EPS. | -- | 23.38 | -- | 40.58 | -- | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | -- |
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015
